Annual report pursuant to Section 13 and 15(d)

Inventory

v3.24.0.1
Inventory
12 Months Ended
Nov. 30, 2023
Inventory Disclosure [Abstract]  
Inventory

NOTE 2 – INVENTORY

Inventory is comprised of public cord blood banking specimens, collection kits, finished goods, work-in-process and raw materials. Collection kits are used in the collection and processing of umbilical cord blood and cord tissue stem cells, finished goods include products purchased or assumed for resale and for the use in the Company’s processing and storage service. Inventory in the Public Cord Blood Bank includes finished goods that are specimens that are available for resale. The Company considers inventory in the Public Cord Blood Bank that has not completed all testing to determine viability to be work in process. Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $3,737,133 and $0 was recognized during the fourth quarter of fiscal 2023 and 2022, respectively, to reduce inventory to net realizable value and is included in the accompanying consolidated statements of operations.

The components of inventory at November 30, 2023 and November 30, 2022 are as follows:

 

 

 

As of
November 30, 2023

 

 

As of
November 30, 2022

 

Raw materials

 

$

 

 

$

 

Work-in-process

 

 

341,692

 

 

 

254,953

 

Work-in-process – Public Bank

 

 

 

 

 

 

Finished goods

 

 

48,045

 

 

 

62,554

 

Finished goods – Public Bank

 

 

5,599,238

 

 

 

9,775,322

 

Collection kits

 

 

47,739

 

 

 

41,463

 

Inventory reserve

 

 

(7,718

)

 

 

(7,718

)

Total inventory

 

$

6,028,996

 

 

$

10,126,574